Future Market Insights recently published a study projecting a value CAGR of 5.97% for the global autosomal dominant polycystic kidney disease treatment market from 2023 to 2033. The market is expected to reach an estimated value of US$ 2,140 million during the forecast period. The availability of special regulatory designations is driving market growth, with an increase in ADPKD treatment trials also contributing to industry expansion. Additionally, the introduction and approval of new ADPKD treatment drugs by regulatory authorities is expected to boost industry growth.
Request a report sample to gain comprehensive insights@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16623
Drug manufacturers stand to benefit from market exclusivity during a specified period, as well as clinical trial tax credits and treatment aid, which can help expand the market. Technological advancements and the development of a wide range of drugs are also expected to propel the market’s growth, enabling clinicians to better assist ADPKD patients. Government initiatives, such as those implemented by the Polycystic Kidney Foundation, aimed at increasing awareness about ADPKD treatment, are also expected to drive market growth.
However, the high cost of ADPKD treatment remains a significant restraining factor, as does the shortage of trained professionals in the industry.
Key Takeaways
- North America is predicted to dominate the industry by the end of the forecast period, with a market share of roughly 39.5%.
- East Asia’s market is expected to grow at the fastest rate of 6.2% over the forecast period.
- Pain and inflammation is expected to account for 37.4% of the market by the end of the forecast period.
- Hospital pharmacies are predicted to lead the market by distribution channel, accounting for 54% of the market by 2033.
“One primary factor that will lead to the expansion of the global polycystic kidney disease drug market is the increasing availability of favourable reimbursement policies. Off-label medications are majorly given to people with polycystic kidney disease,” comments an FMI analyst.
Ask More About This Market’s Geographical Distribution Along With a Detailed Analysis of the Top Regions@ https://www.futuremarketinsights.com/ask-question/rep-gb-16623
Competitive Landscape
The Autosomal dominant polycystic kidney disease treatment market is intensely competitive and consists of several industry players. These players are developing novel delivery systems for treating Autosomal dominant polycystic kidney disease treatment. This is estimated to propel Autosomal dominant polycystic kidney disease treatment market. The key players in this industry are: Otsuka Pharmaceutical, Sanofi, Reata Pharmaceuticals, Galapagos NV, Janssen Pharmaceuticals, Regulus Therapeutics, Xortx Therapeutics, AceLink Therapeutics, Inc., PanoTherapeutics, Inc., and Exelixis, Inc. Some recent developments in the market are:
- Grupo Olmos, a provider of renal care solutions, announced in July 2022 that it had purchased the renal care business of Diaverum, an Argentine renal healthcare provider. This acquisition will help the company’s renal product portfolio.
- Palladio Biosciences announced in 2020 that the first patient with autosomal dominant polycystic kidney disease has been dosed with lixivaptan, a new vasopressin V2 antagonist. They confirmed the safety of lixivaptan in these individuals who had previously stopped using tolvaptan due to liver damage.
- Aster Hospitals, one of the largest private healthcare service providers in the GCC, said in March 2019 that it had launched an awareness and screening effort to promote the prevention of chronic kidney disease through education, awareness, and early diagnosis.
- Bayer announced the launch of finerenone, a medication used to treat chronic kidney disease associated with type 2 diabetes, in India in August 2022.
- Health Canada accepted GlaxoSmithKline’s New Drug Submission for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for the treatment of chronic kidney disease anaemia, in July 2022.
More Valuable Insights Available
Future Market Insights offers an unbiased analysis of the global Autosomal dominant polycystic kidney disease treatment market, providing historical data for 2018 to 2022 and forecast statistics from 2023 to 2033.
Buy Now to Gain Access to Detailed Information About Each Segment and Identify Key Trends, Drivers, and Challenges in the Market@ https://www.futuremarketinsights.com/checkout/16623
Key Segments Profiled in the Autosomal Dominant Polycystic Kidney Disease Treatment Industry Survey
By Treatment Type:
- Pain & Inflammation Treatment
- Kidney Stone Treatment
- Urinary Tract Infection Treatment
- Kidney Failure Treatment
By End User:
- Hospitals
- Clinics
- Ambulatory Surgical Centers
About the Healthcare Division at Future Market Insights
The healthcare team at Future Market Insights offers expert analysis, time efficient research, and strategic recommendations with an objective to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 million+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis on key trends including competitive landscape, profit margin, and research development efforts.
About Future Market Insights, Inc.
Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs
